(Q33832646)

29 July 2017

1 reference

title

Antiandrogens in prostate cancer (English)

1 reference

29 July 2017

1 reference

2

Kantoff P

1 reference

29 July 2017

Reid P

1

1 reference

PubMed ID

10665479

29 July 2017

Oh W

series ordinal

3

1 reference

29 July 2017

1 January 1999

1 reference

Investigational New Drugs

29 July 2017

1 reference

29 July 2017

17

1 reference

29 July 2017

271-284

1 reference

29 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006344807086

29 July 2017

0 references

cites work

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

1 reference

12 December 2020

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

12 December 2020

Effect of Finasteride, a 5α-Reductase Inhibitor on Prostate Tissue Androgens and Prostate-Specific Antigen*

1 reference

12 December 2020

Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone

1 reference

12 December 2020

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

12 December 2020

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

12 December 2020

Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA

1 reference

12 December 2020

A new non-steroidal anti-androgen

1 reference

12 December 2020

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years

1 reference

12 December 2020

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.

1 reference

12 December 2020

Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy

1 reference

12 December 2020

Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature

1 reference

12 December 2020

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

12 December 2020

Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study

1 reference

12 December 2020

Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients

1 reference

12 December 2020

Experience with Flutamide in Previously Untreated Patients With Advanced Prostatic Cancer

1 reference

12 December 2020

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

1 reference

12 December 2020

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

1 reference

12 December 2020

Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer

1 reference

12 December 2020

Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP)

1 reference

12 December 2020

Antiandrogen withdrawal syndrome with cyproterone acetate

1 reference

12 December 2020

Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation

1 reference

12 December 2020

Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project

1 reference

12 December 2020

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

12 December 2020

Importance of continued testicular suppression in hormone-refractory prostate cancer

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol

1 reference

12 December 2020

Acute cholestatic hepatitis secondary to flutamide therapy

1 reference

12 December 2020

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

12 December 2020

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1 reference

12 December 2020

Localization of functional domains in the androgen receptor

1 reference

12 December 2020

The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue

1 reference

12 December 2020

Near fatal liver dysfunction secondary to administration of flutamide for prostate cancer

1 reference

12 December 2020

Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review

1 reference

12 December 2020

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

1 reference

12 December 2020

Combined finasteride and flutamide therapy in men with advanced prostate cancer

1 reference

12 December 2020

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer

1 reference

12 December 2020

High-dose bicalutamide monotherapy for the treatment of prostate cancer

1 reference

12 December 2020

Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance

1 reference

12 December 2020

Use of cyproterone acetate in prostate cancer.

1 reference

12 December 2020

Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

1 reference

12 December 2020

Antiandrogen withdrawal syndrome with nilutamide

1 reference

12 December 2020

Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators

1 reference

12 December 2020

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

1 reference

12 December 2020

Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH)

1 reference

12 December 2020

Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urol

1 reference

12 December 2020

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial.

1 reference

12 December 2020

A structural role for hormone in the thyroid hormone receptor.

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma

1 reference

12 December 2020

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

1 reference

12 December 2020

Androgen receptor gene mutations in human prostate cancer

1 reference

12 December 2020

Total androgen ablation: Canadian experience

1 reference

12 December 2020

The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma

1 reference

12 December 2020

Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy

1 reference

12 December 2020

Estramustine potentiates the effects of irradiation on the Dunning (R3327) rat prostatic adenocarcinoma

1 reference

12 December 2020

A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences

1 reference

12 December 2020

Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cance

1 reference

12 December 2020

Prolonged treatment with finasteride (a 5α‐reductase inhibitor) does not affect bone density and metabolism

1 reference

12 December 2020

Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy

1 reference

12 December 2020

Severe hepatitis caused by cyproterone acetate

1 reference

12 December 2020

Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells

1 reference

12 December 2020

Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide

1 reference

12 December 2020

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

1 reference

12 December 2020

Megestrol acetate in the treatment of hormone refractory prostate cancer

1 reference

12 December 2020

Phase II study of megestrol acetate for metastatic carcinoma of the prostate

1 reference

12 December 2020

The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study.

1 reference

12 December 2020

Androgen-regulated gene expression in prostate cancer

1 reference

12 December 2020

Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers

1 reference

12 December 2020

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

12 December 2020

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

1 reference

12 December 2020

Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer

1 reference

12 December 2020

Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group

1 reference

12 December 2020

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome

1 reference

12 December 2020

Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action

1 reference

12 December 2020

The preclinical development of bicalutamide: pharmacodynamics and mechanism of action

1 reference

12 December 2020

Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha

1 reference

12 December 2020

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

12 December 2020

Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones

1 reference

12 December 2020

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

12 December 2020

Activation of programmed cell death in the rat ventral prostate after castration

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006344807086

1 reference

PubMed ID

10665479

Dimensions Publication ID

29 July 2017

0 references

1 reference

PubMed ID

10665479